Related Experiment Video

Updated: Jul 13, 2026

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
09:43

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids

Published on: October 14, 2019

Multiple endocrine neoplasia type II

S A Wells, D A Ontjes

    Annual Review of Medicine
    |January 1, 1976
    PubMed

    Insights

    Early diagnosis of medullary thyroid carcinoma (MCT) in Multiple Endocrine Neoplasia type II (MEN-II) families is crucial. Further research into novel chemotherapeutic agents for metastatic MCT is warranted.

    Area of Science:

    • Endocrinology
    • Oncology
    • Genetics

    Background:

    • Multiple Endocrine Neoplasia type II (MEN-II) is a genetic disorder associated with an increased risk of medullary thyroid carcinoma (MCT).
    • Timely diagnosis and management of MEN-II are essential for patient outcomes.

    Purpose of the Study:

    • To review the clinical characteristics, diagnostic methods, and treatment of MEN-II.
    • To emphasize the importance of early MCT detection in MEN-II families.
    • To identify future research directions for metastatic MCT treatment.

    Main Methods:

    • Review of clinical characteristics, diagnostic approaches, and therapeutic strategies for MEN-II.
    • Analysis of current literature regarding MCT in MEN-II patients.

    Main Results:

    • Clinical features, diagnostic criteria, and treatment options for MEN-II have been outlined.
    • The necessity for early identification of MCT in at-risk family members is highlighted.

    Conclusions:

    • Future efforts should prioritize the early diagnosis of MCT within MEN-II kindreds.
    • Investigating novel chemotherapeutic or antitumor agents for metastatic MCT presents a promising research avenue.

    More Related Videos

    Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

    Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

    Published on: August 25, 2023

    Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models08:57

    Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

    Published on: May 17, 2024

    Related Concept Videos

    Cancer-Critical Genes II: Tumor Suppressor Genes01:05

    Cancer-Critical Genes II: Tumor Suppressor Genes

    Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
    When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
    Such genes that act...
    Hyperthyroidism II: Pathophysiology01:27

    Hyperthyroidism II: Pathophysiology

    Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
    Cushing Syndrome II: Pathophysiology01:19

    Cushing Syndrome II: Pathophysiology

    Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
    Type I Diabetes II: Pathophysiology01:26

    Type I Diabetes II: Pathophysiology

    Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
    Type II Diabetes I: Introduction01:26

    Type II Diabetes I: Introduction

    Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
    Type II Diabetes II: Pathophysiology01:24

    Type II Diabetes II: Pathophysiology

    PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.